[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nextcure Inc (NXTC)

Nextcure Inc (NXTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,315
  • Shares Outstanding, K 3,612
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,840 K
  • EBIT $ -56 M
  • EBITDA $ -54 M
  • 60-Month Beta 1.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.98
  • Number of Estimates 2
  • High Estimate $-1.93
  • Low Estimate $-2.03
  • Prior Year $-11.29
  • Growth Rate Est. (year over year) +82.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.55 +173.55%
on 06/26/26
9.90 -57.17%
on 07/14/26
+2.47 (+139.55%)
since 06/24/26
3-Month
1.55 +173.55%
on 06/26/26
11.14 -61.94%
on 05/14/26
-6.28 (-59.70%)
since 04/24/26
52-Week
1.55 +173.55%
on 06/26/26
15.74 -73.06%
on 11/24/25
-1.02 (-19.39%)
since 07/24/25

Most Recent Stories

More News
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB

NEW YORK , July 22, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

FHB : 28.11 (-1.88%)
VEEE : 12.97 (-10.55%)
NXTC : 4.24 (+1.44%)
TCBK : 58.12 (-1.96%)
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

CRNX : 83.73 (+0.10%)
VEEE : 12.97 (-10.55%)
NXTC : 4.24 (+1.44%)
TCBK : 58.12 (-1.96%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)

NEW YORK , July 14, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

NXTC : 4.24 (+1.44%)
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE , July 14, 2026 /PRNewswire/ -- Ademi LLP is investigating NextCure (NASDAQ: NXTC) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

NXTC : 4.24 (+1.44%)
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...

NXTC : 4.24 (+1.44%)
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as...

NXTC : 4.24 (+1.44%)
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer,...

NXTC : 4.24 (+1.44%)
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerability...

NXTC : 4.24 (+1.44%)
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

SIM0505/CDH6 ADC dose optimization initiated in gynecologic cancers SIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026 LNCB74 Phase 1 dose escalation trial update planned in...

NXTC : 4.24 (+1.44%)
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

Dose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC)  Phase 1 data readout to be presented at ASCO 2026 BELTSVILLE, Md.,...

NXTC : 4.24 (+1.44%)

Business Summary

NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland....

See More

Key Turning Points

3rd Resistance Point 5.03
2nd Resistance Point 4.78
1st Resistance Point 4.51
Last Price 4.24
1st Support Level 3.99
2nd Support Level 3.74
3rd Support Level 3.47

See More

52-Week High 15.74
Fibonacci 61.8% 10.32
Fibonacci 50% 8.64
Fibonacci 38.2% 6.97
Last Price 4.24
52-Week Low 1.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.